A Phase II, multicenter, randomized, double-blind, parallel gruop, placebo-controlled, adaptive dose-ranging study to eveluate the efficacy and safety of AIN457 (Secuinumab) (IV) inn patients with relapsing mutiple sclerosis.
Clinical Trial Grant
Administered By
Neurology, MS & Neuroimmunology
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
May 1, 2013
End Date
March 31, 2016
Administered By
Neurology, MS & Neuroimmunology
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
May 1, 2013
End Date
March 31, 2016